Редактирование: Aging genes 3-9 (раздел)

==CYP2D6==

* {{medline-title
|title=Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
|date=05.2019
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/30985942
|full-text-url=https://sci-hub.do/10.1002/bdd.2181
}}
* {{medline-title
|title=[Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].
|date=2018
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/30175758
|full-text-url=https://sci-hub.do/10.1248/yakushi.18-00114
}}
* {{medline-title
|title=Analysis of the variability of the pharmacokinetics of multiple drugs in young adult and elderly subjects and its implications for acceptable daily exposures and cleaning validation limits.
|date=06.2017
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/28396010
|full-text-url=https://sci-hub.do/10.1016/j.ijheh.2017.03.007
}}
* {{medline-title
|title=Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known [[CYP2D6]] Genotype.
|date=11.2016
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/27145399
|full-text-url=https://sci-hub.do/10.1111/bcpt.12614
}}
* {{medline-title
|title=Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI.
|date=05.2015
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/25257248
|full-text-url=https://sci-hub.do/10.1007/s00702-014-1317-9
}}
* {{medline-title
|title=Impact of age on serum concentrations of venlafaxine and escitalopram in different [[CYP2D6]] and [[CYP2C19]] genotype subgroups.
|date=08.2014
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/24858822
|full-text-url=https://sci-hub.do/10.1007/s00228-014-1696-8
}}